Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2024-12-09 00:00:00 ET · period of report 2024-10-30 · accession 0000950170-24-134524 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-09 | 2024-12-01 | INKT | Kadlec Robert Peter | Dir | A - Grant | $0.73 | +12.3K | 12.3K | New | +$8,969 |
| D | 2024-12-09 | 2024-10-30 | INKT | Kadlec Robert Peter | Dir | A - Grant | $0.00 | +41.7K | 41.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-01 | A | A | 12,286 | $0.73 | 12,286 | D | — | — | (F2) Dr. Kadlec was granted restricted stock unites ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. |
| 2 | Derivative | Stock Option | 2024-10-30 | A | A | 41,745 | $0.00 | 41,745 | D | $0.72 · — to 2034-10-30 | 41,745 Common Stock | (F1) The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on October 30, 2024 and will vest in three equal annual installments on each of October 30, 2025, 2026 and 2027 (provided Dr. Kadlec maintains a service relationship with the company through each such vesting date). |